Digital Treatment of Irritable Bowel Syndrome (IBS)

NCT ID: NCT06117865

Last Updated: 2025-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

728 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-01

Study Completion Date

2033-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this work is to identify whether the digital treatment program Mage-tarmskolen has an effect on patients with IBS. Our secondary objectives is to address multiple aspects of digital treatmtent success of the different modules. The patients will be randomized to one of four arms and will be delivered different kinds of digital treatment. All patients will have access to ask questions to a registered dietitian. Primary end point is the proportion of patients with treatment success in the low FODMAP, behavioral therapy or both groups, versus the patient education group (sham). Treatment effect is defined as an improvement of 50 points or more on the IBS severity scoring system at 3 months after treatment start compared to the score before treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IBS - Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient education

Group Type SHAM_COMPARATOR

Module 1

Intervention Type BEHAVIORAL

Module 1: Introduction to IBS by a gastroenterologist.

Module 2

Intervention Type BEHAVIORAL

Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.

Module 3

Intervention Type BEHAVIORAL

Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.

Behavioral therapy

Group Type ACTIVE_COMPARATOR

Module 1

Intervention Type BEHAVIORAL

Module 1: Introduction to IBS by a gastroenterologist.

Module 2

Intervention Type BEHAVIORAL

Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.

Module 3

Intervention Type BEHAVIORAL

Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.

Module 4

Intervention Type BEHAVIORAL

Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).

Low FODMAP-diet

Group Type ACTIVE_COMPARATOR

Module 1

Intervention Type BEHAVIORAL

Module 1: Introduction to IBS by a gastroenterologist.

Module 2

Intervention Type BEHAVIORAL

Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.

Module 3

Intervention Type BEHAVIORAL

Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.

Module 5

Intervention Type BEHAVIORAL

Module 5: Intervention: The low FODMAP diet.

Combined treatment

Low FODMAP-diet and behavioral therapy

Group Type ACTIVE_COMPARATOR

Module 1

Intervention Type BEHAVIORAL

Module 1: Introduction to IBS by a gastroenterologist.

Module 2

Intervention Type BEHAVIORAL

Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.

Module 3

Intervention Type BEHAVIORAL

Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.

Module 4

Intervention Type BEHAVIORAL

Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).

Module 5

Intervention Type BEHAVIORAL

Module 5: Intervention: The low FODMAP diet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Module 1

Module 1: Introduction to IBS by a gastroenterologist.

Intervention Type BEHAVIORAL

Module 2

Module 2:Introduction to pain physiology and how the nervous system works by a physiotherapist including practical exercises.

Intervention Type BEHAVIORAL

Module 3

Module 3: Evidence-based guidelines for diet and lifestyle advice (NICE Guidelines) by a clinical dietitian.

Intervention Type BEHAVIORAL

Module 4

Module 4: Intervention: behavioral therapy (exposure therapy and cognitive behavioral therapy).

Intervention Type BEHAVIORAL

Module 5

Module 5: Intervention: The low FODMAP diet.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Diagnosed with IBS in the primary or secondary healthcare service.

* Patients aged 18-70 years with IBS defined by the Rome IV criteria: Recurrent abdominal pain, on average at least 1 day per week during the previous 3 months, that is associated with two or more of the following: i) Defecation, either increased pain or pain relief, ii) Change in stool frequency, iii) Change in stool form (appearance)
* All participants \>50 years: Colonoscopy within the last 5 years prior to study entry excluding other pathology
* Bank-ID and access to tablet, PC or smart phone.
* No known presence of: symptomatic endometriosis, Diabetes type 1 and 2, Malignant disease (excluding basalioma),
* No history of: severe psychiatric disorder, alcohol or drug abuse, inflammatory bowel disease, microscopic colitis, diverticulitis or ileus, major abdominal surgery (except appendectomy, cholecystectomy, caesarean section, and hysterectomy)
* No "red flags'' indicating severe undiagnosed disease: Night sweats (Repeated episodes of extreme perspiration that may soak nightclothes or bedding), Unintentional weight loss (≥ 4.5 kilograms, or 5% of normal body weight) over less than 6 months without knowing the reason, or blood in stool
* Not pregnant
* Ability to comply with protocol requirements
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Haukeland University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Haukeland University Hospital

Bergen, Vestlandet, Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-630038

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.